236 related articles for article (PubMed ID: 37410451)
1. Radiotherapy Use and Incidence of Locoregional Recurrence in Patients With Favorable-Risk, Node-Positive Breast Cancer Enrolled in the SWOG S1007 Trial.
Jagsi R; Barlow WE; Woodward WA; Connolly E; Mahtani R; Shumway D; Speers C; Stecklein SR; Zeidan Y; Zhang H; Sharma P; Pusztai L; Hortobagyi GN; Kalinsky K
JAMA Oncol; 2023 Aug; 9(8):1083-1089. PubMed ID: 37410451
[TBL] [Abstract][Full Text] [Related]
2. Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.
Woodward WA; Barlow WE; Jagsi R; Buchholz TA; Shak S; Baehner F; Whelan TJ; Davidson NE; Ingle JN; King TA; Ravdin PM; Osborne CK; Tripathy D; Livingston RB; Gralow JR; Hortobagyi GN; Hayes DF; Albain KS
JAMA Oncol; 2020 Apr; 6(4):505-511. PubMed ID: 31917424
[TBL] [Abstract][Full Text] [Related]
3. Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor-Positive, Node-Negative Breast Cancer: A Post Hoc Analysis of the TAILORx Randomized Clinical Trial.
Kantor O; King TA; Freedman RA; Mayer EL; Chavez-MacGregor M; Korde LA; Sparano JA; Mittendorf EA
JAMA Surg; 2023 Jun; 158(6):583-591. PubMed ID: 37043210
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Impact of Regional Nodal Irradiation in Patients With Node-Positive Breast Cancer Treated With Neoadjuvant Systemic Therapy.
Stecklein SR; Park M; Liu DD; Valle Goffin JJ; Caudle AS; Mittendorf EA; Barcenas CH; Mougalian S; Woodward WA; Valero V; Sahin AA; Yang WT; Shaitelman SF
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):568-577. PubMed ID: 29928946
[TBL] [Abstract][Full Text] [Related]
5. Clinical Effectiveness of an Adaptive Treatment Planning Algorithm for Intensity Modulated Radiation Therapy Versus 3D Conformal Radiation Therapy for Node-Positive Breast Cancer Patients Undergoing Regional Nodal Irradiation/Postmastectomy Radiation Therapy.
Bazan JG; Healy E; Beyer S; Kuhn K; DiCostanzo D; Smith TL; Jhawar S; White JR
Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1159-1171. PubMed ID: 32711036
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for regional nodal failure after breast-conserving therapy: regional nodal irradiation reduces rate of axillary failure in patients with four or more positive lymph nodes.
Grills IS; Kestin LL; Goldstein N; Mitchell C; Martinez A; Ingold J; Vicini FA
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):658-70. PubMed ID: 12788171
[TBL] [Abstract][Full Text] [Related]
7. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
[TBL] [Abstract][Full Text] [Related]
8. Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.
Gingras I; Holmes E; De Azambuja E; Nguyen DH; Izquierdo M; Anne Zujewski J; Inbar M; Naume B; Tomasello G; Gralow JR; Wolff AC; Harris L; Gnant M; Moreno-Aspitia A; Piccart MJ; Azim HA
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376188
[TBL] [Abstract][Full Text] [Related]
9. Association Between Regional Nodal Irradiation and Breast Cancer Recurrence-Free Interval for Patients With Low-Risk, Node-Positive Breast Cancer.
Sit D; Lalani N; Chan E; Tran E; Speers C; Gondara L; Chia S; Gelmon K; Lohrisch C; Nichol A
Int J Radiat Oncol Biol Phys; 2022 Mar; 112(4):861-869. PubMed ID: 34762971
[TBL] [Abstract][Full Text] [Related]
10. Does Failure to Achieve Pathologic Complete Response with Neoadjuvant Chemotherapy Identify Node-Negative Patients Who Would Benefit from Postmastectomy Radiation or Regional Nodal Irradiation?
Crown A; Gonen M; Le T; Morrow M
Ann Surg Oncol; 2021 Mar; 28(3):1328-1335. PubMed ID: 32959140
[TBL] [Abstract][Full Text] [Related]
11. Predictors of locoregional outcome in HER2-overexpressing breast cancer treated with neoadjuvant chemotherapy.
Arsenault D; Hurley J; Takita C; Reis IM; Zhao W; Rodgers S; Wright JL
Am J Clin Oncol; 2015 Aug; 38(4):348-52. PubMed ID: 23799288
[TBL] [Abstract][Full Text] [Related]
12. Breast carcinoma with 21-gene recurrence score lower than 18: rate of locoregional recurrence in a large series with clinical follow-up.
Turashvili G; Brogi E; Morrow M; Dickler M; Norton L; Hudis C; Wen HY
BMC Cancer; 2018 Jan; 18(1):42. PubMed ID: 29304773
[TBL] [Abstract][Full Text] [Related]
13. 21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.
Mamounas EP; Liu Q; Paik S; Baehner FL; Tang G; Jeong JH; Kim SR; Butler SM; Jamshidian F; Cherbavaz DB; Sing AP; Shak S; Julian TB; Lembersky BC; Wickerham DL; Costantino JP; Wolmark N
J Natl Cancer Inst; 2017 Jan; 109(4):. PubMed ID: 28122895
[TBL] [Abstract][Full Text] [Related]
14. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
[TBL] [Abstract][Full Text] [Related]
15. Incidence and time of occurrence of regional recurrence in stage I-II breast cancer: value of adjuvant irradiation.
Fodor J; Toth J; Major T; Polgar C; Nemeth G
Int J Radiat Oncol Biol Phys; 1999 May; 44(2):281-7. PubMed ID: 10760420
[TBL] [Abstract][Full Text] [Related]
16. Impact of Radiation on Locoregional Control in Women with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy and Axillary Lymph Node Dissection: Results from ACOSOG Z1071 Clinical Trial.
Haffty BG; McCall LM; Ballman KV; Buchholz TA; Hunt KK; Boughey JC
Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):174-182. PubMed ID: 31085287
[TBL] [Abstract][Full Text] [Related]
17. Mastectomy alone for pT1-2 pN0-1 breast cancer patients: when postmastectomy radiotherapy is indicated.
Leonardi MC; Scognamiglio IR; Maisonneuve P; Dicuonzo S; Rojas DP; Zerella MA; Morra A; Gerardi MA; Zaffaroni M; De Scalzi A; Girardi A; Magnoni F; Montagna E; Fodor CI; Galimberti VE; Veronesi P; Orecchia R; Pacelli R; Jereczek-Fossa BA; Corso G
Breast Cancer Res Treat; 2021 Jul; 188(2):511-524. PubMed ID: 33905020
[TBL] [Abstract][Full Text] [Related]
18. Locoregional failure of postmastectomy patients with 1-3 positive axillary lymph nodes without adjuvant radiotherapy.
Cheng JC; Chen CM; Liu MC; Tsou MH; Yang PS; Jian JJ; Cheng SH; Tsai SY; Leu SY; Huang AT
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):980-8. PubMed ID: 11958892
[TBL] [Abstract][Full Text] [Related]
19. Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?
Mamtani A; Patil S; Stempel MM; Morrow M
Cancer; 2017 Jul; 123(14):2626-2633. PubMed ID: 28334423
[TBL] [Abstract][Full Text] [Related]
20. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.
Mamounas EP; Anderson SJ; Dignam JJ; Bear HD; Julian TB; Geyer CE; Taghian A; Wickerham DL; Wolmark N
J Clin Oncol; 2012 Nov; 30(32):3960-6. PubMed ID: 23032615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
